Yamamoto-Furusho J K, Gutiérrez-Grobe Y, López-Gómez J G, Bosques-Padilla F, Rocha-Ramírez J L
Clínica de Enfermedad Inflamatoria Intestinal, Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
Clínica de Enfermedad Inflamatoria Intestinal, Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
Rev Gastroenterol Mex (Engl Ed). 2018 Apr-Jun;83(2):144-167. doi: 10.1016/j.rgmx.2017.08.006. Epub 2018 Mar 2.
The guidelines presented herein are an updated version of the recommendations published in 2007. Since then, there has been a rapid advance in the knowledge about the pathophysiology of ulcerative colitis and its therapeutic options. New drugs have been approved, novel targeted therapies have emerged, and new strategies have been developed to improve the previously available approaches to the disease. The aim of the present consensus is to promote the current knowledge of and Mexican perspective on the epidemiology, diagnosis, and medical and surgical treatment of chronic idiopathic ulcerative colitis. The final vote on the statements and their ultimate modifications were carried out at the consensus working group meeting. Evidence was evaluated through the GRADE classification.
本文提出的指南是2007年发布的建议的更新版本。自那时以来，关于溃疡性结肠炎的病理生理学及其治疗选择的知识有了迅速进展。新药物已获批准，新型靶向治疗方法已经出现，并且已经制定了新策略来改进以前针对该疾病的可用方法。本共识的目的是推广关于慢性特发性溃疡性结肠炎的流行病学、诊断以及内科和外科治疗的当前知识和墨西哥观点。对声明及其最终修改的最终投票在共识工作组会议上进行。证据通过GRADE分类进行评估。
